Compare C3.ai Inc (AI) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
C3.ai Inc vs Amgen, Inc. — how do they compare? C3.ai Inc trades at $10.54 (market cap $1.65B), while Amgen, Inc. trades at $412.77 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 135.8× C3.ai Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | AMGN | |
|---|---|---|
Market Cap | $1.65B | $224.14B |
Sector | Technology | Health |
52-Week High | $19.66 | $417.20 |
52-Week Low | $7.76 | $271.18 |
Enterprise Value | $1.08B | $267.45B |
Dividend Yield | — | 2.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
